Ikarian Capital, LLC Viking Therapeutics, Inc. Call Options Transaction History
Ikarian Capital, LLC
- $247 Million
- Q2 2024
Call Options
1 transactions
Others Institutions Holding VKTX
# of Institutions
478Shares Held
66.1MCall Options Held
6.24MPut Options Held
3.01M-
Vanguard Group Inc Valley Forge, PA10.1MShares$695 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$415 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$353 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$155 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$128 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $5.28B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...